In addition, a recently published case series provided preliminary evidence supporting the slower growth rate of TSC-associated PanNETs in patients taking an mTOR inhibitor compared to those with no treatment, but further investigation is required to suggest the use of mTOR inhibitors as the first-line medical treatment or an alternative to surgical removal in TSC patients with nonfunctioning PanNETs [101]. The gene discussed is MTOR; the disease is tuberous sclerosis.